Compugen (CGEN) Non-Current Assets (2009 - 2026)
Compugen (CGEN) posted quarterly Non-Current Assets of $8.6 million for Q1 2026, little changed year-over-year from $8.5 million in Q1 2025, and little changed on a QoQ basis from $8.5 million in Q4 2025.
Analysis
Compugen (CGEN) Non-Current Assets (2009 - 2026) Analysis & Trends
Compugen has reported Non-Current Assets for 18 years, with the latest figure at $8.6 million in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $8.6 million, changed 0.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.6 million (changed 0.32% YoY), and the FY2025 annual result was $8.5 million, down 5.0% from the prior year.
- Non-Current Assets held at $8.6 million in Q1 2026, from $8.5 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $9.0 million in Q4 2024 and troughed at $6.8 million in Q4 2023.
- A 5-year average of $8.3 million and a median of $8.3 million in 2022 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2023, when Non-Current Assets declined 16.1%; it then jumped 33.21% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $8.1 million in 2022, then declined by 16.1% to $6.8 million in 2023, then jumped by 33.21% to $9.0 million in 2024, then slipped by 5.0% to $8.5 million in 2025, then rose by 0.34% to $8.6 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $8.6 million in Q1 2026, $8.5 million in Q4 2025, and $8.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Compugen | 242.44 Mn | 156.82 Mn | -92,000.00 | 8.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.96 Mn |
| Mar 31, 2026 | 8.58 Mn |
| Dec 31, 2025 | 8.55 Mn |
| Sep 30, 2025 | 8.93 Mn |
| Jun 30, 2025 | 8.88 Mn |
| Mar 31, 2025 | 8.55 Mn |
| Dec 31, 2024 | 9.00 Mn |
| Sep 30, 2024 | 8.69 Mn |
| Jun 30, 2024 | 8.03 Mn |
| Mar 31, 2024 | 8.13 Mn |
| Dec 31, 2023 | 6.76 Mn |
| Sep 30, 2023 | 7.34 Mn |
| Jun 30, 2023 | 7.66 Mn |
| Mar 31, 2023 | 7.88 Mn |
| Dec 31, 2022 | 8.05 Mn |
| Sep 30, 2022 | 8.33 Mn |
| Jun 30, 2022 | 8.33 Mn |
| Mar 31, 2022 | 8.81 Mn |
| Dec 31, 2021 | 8.94 Mn |
| Sep 30, 2021 | 9.01 Mn |